54 results about "Miconazole" patented technology

The invention relates to an edible fungus cultivating material prepared by utilizing waste Chinese medicinal residues and a preparation method thereof in the technical field of plant cultivation. The edible fungus cultivating material comprises the following components in part by weight: 50 to 70 parts of Chinese medicinal residue, 10 to 20 parts of cotton seed hull, 5 to 10 parts of corn flour, 2 to 5 parts of calcium oxide, 5 to 10 parts of nitrogenous fertilizer, 2 to 4 parts of monopotassium phosphate, 0.1 to 0.2 part of miconazole, 0.4 to 0.8 part of microelements and 0.2 to 0.4 part of molysite. The method solves the problem of environmental pollution of the waste Chinese medicinal residue, relieves the pollution treatment burden of enterprises, solves the problems of shortage and price rise of the edible fungus cultivating material, saves the production cost and produces high-quality functional edible fungus products.

This invention relates to a method of treating otitis externa, and in particular otitis externa of fungal etiology, using topical medication, including antifungal agents such as itraconazole and miconazole, and optionally also including a second antifungal agent, which is formulated for topical application to the external ear canal, preferably as an ear drop in liquid form.

Antimicrobial and contraceptive compositions and methods which prevent and / or reduce the risk of transmission of sexually transmitted diseases through sexual activity as well as prevent and / or reduce the risk of pregnancy are provided. The compositions contain (1) a matrix-forming agent, (2) a bio-adhesive agent, (3) a buffering agent, (4) optionally a humectant, (5) optionally a preservative, and (6) water; wherein the composition is suitable for application within the vagina; wherein the compositions form a semisolid matrix on contact with ejaculate (thereby trapping ejaculated microbes and spermatozoa); wherein the composition causes hardening of cervical mucus (thereby decreasing the probability of sperm entry); wherein the composition forms a bio-adhesive layer over vaginal surfaces (thereby preventing or reducing the risk of contact of STD-causing microbes with the vaginal surfaces); wherein the composition maintains an acidic vaginal pH of less than about 5 in the presence of semen ejaculated from the male; and wherein the composition does not significantly impair the natural microbiological balance within the vagina. The antimicrobial and contraceptive compositions may also contain additional antimicrobial and / or contraceptive agents (e.g., nonoxynol-9, octoxynol-9, benzalkonium chloride, phosphorylated hesperidins, sulfonated hesperidins, polystyrene sulfonates, substituted benzenesulfonic acid formaldehyde co-polymers, H2SO4-modified mandelic acids, povidone iodine, itraconazole, ketoconazole, metronidazole, clotrimazole, fluconazole, teraconazole, miconazole, tinidazole, iconazole, chloramphenicol, nystatin, cyclopiroxolamine, and the like).

The invention relates to the technical field of medicaments, in particular to novel application of kaempferol as a synergist of anti-fungal medicaments. The anti-fungal medicaments are azole-type or polyene-type anti-fungal medicaments and based on the effective concentration of the anti-fungal medicaments, the adding ratio of the kaempferol is 0.5 to 16 mu g / ml. Tests show that when the kaempferol and the anti-fungal medicaments such as fluconazole, ketoconazole, miconazole and amphotericin B are used together, not only the anti-fungal effect is guaranteed on the premise of lowering the consumption of the anti-fungal medicaments, but also the anti-fungal medicaments can restore the function of killing the drug-resistant fungi, so that the kaempferol can be used as a synergist of the anti-fungal medicaments. The kaempferol used as the synergist of the anti-fungal medicaments can lower the consumption of the azole-type or polyene-type anti-fungal medicaments so as to reduce the toxic and side effects of the medicaments; and the kaempferol can make the anti-fungal medicaments restore the function of killing the drug-resistant fungi, so that the kaempferol can effectively treat mycotic infection, particularly drug-resistant t mycotic infection, and has quite important clinical application values.

The present invention relates to medicine technology and is especially new use of baicalein, which is one kind of effective components extracted from skullcap root and has been used in treating various kinds of inflammation, as antifungal medicine synergist. Baicalein is added into antifungal pyrrole medicine in the added amount of 4-16 mcg / ml. Experiments show that adding baicalein into antifungal medicine of fluconazole, ketocanazole, miconazole, etc can ensure the treating effect on fungal inflection and resist the drug tolerance of drug resisting fungi, so that baicalein may be used as the synergist of antifungal medicine.

The present invention encompasses anhydrous micogel formulations containing miconazole and methods of use for the treatment of topical disorders including acne.

The invention discloses an externally-used medicament for treating skin mycosis diseases, which is prepared from the raw materials of (by weight percent) terbinafine hydrochloride or miconazole or ketoconazole 0. 5-2%, Clobetasol Propionate 0. 01-0. 2%, neomycin sulphate 0. 3-1%, bee glue 5-25%, and balancing distilled water.

A method for local treatment of severe oral lesions caused by oropharyngeal candidiasis in immunocompromised patients, in particularly having head and neck cancer and undergoing or have undergone radiation therapy, by administering a prolonged release mucoadhesive tablet containing at least one active principle of miconazole. Methods of treating xerostomia in cancer patients having severe oral lesions is also provided.

The invention provides application of magnolol and azole medicines to preparation of antifungal combined medicines. The application indicates that azole medicines such as fluconazole, ketoconazole, itraconazole, miconazole and voriconazole are used together with magnolol to generate a synergetic antifungal effect; the magnolol serving as an efflux pump Cdrlp substrate is utilized to compete with the azole medicines for an efflux system, so that the concentration of efflux medicines can be reduced, and the curative effect of medicines can be improved. Furthermore, magnolol acts on the synthetic pathway of ergosterol and is combined with azole medicines to form a double-edged sword to inhibit synthesis of ergosterol together.

The invention discloses a medicinal composition for treating mycotic infection at the superficial part and application thereof. The medicinal composition comprises miconazole and hanfangchin A, wherein the concentration of the hanfangchin A in a miconazole and hanfangchin A combined system is more than or equal to 40mug / ml. The medicinal composition can be used for an active component for preparing a medicament for treating the mycotic infection at the superficial part. After being verified by an in-vitro antimicrobial test, the hanfangchin A can be used for enhancing the antimycotic effect of the miconazole on dermatophyte and monilial to different degrees, in particular bacteriostasis effect on medicament-resistant fungi; and meanwhile, the dosage of the miconazole is reduced.

The invention relates to a miconazole intermediate biosynthesis method. The biosynthesis method is characterized in that a miconazole intermediate [(R)-2-chlorine-1-(2,4-dichlorophenyl)-ethanol] witha high chiral ee value (ee is greater than 99) is prepared by catalyzing a substrate 2-chlorine-1-(2,4-dichlorophenyl)ethanone by carbonyl reductase in an enzyme database of carbonyl reductase in a laboratory; the carbonyl reductase is Candida macedoniensis AKU 4588; an addition of the carbonyl reductase is 20-100 U / L; the catalyzed synthesis condition is characterized in that in a buffer solutionwith a pH value being 7.6-8.8, and the miconazole intermediate [(R)-2-chlorine-1-(2,4-dichlorophenyl)-ethanol] is synthesized by catalyzing a reaction of the substrate 2-chlorine-1-(2,4-dichlorophenyl) ethanone at the temperature of 30-40 DEG C and under condition of existence of Zn2+. The method mainly substitutes a traditional chemical synthetic method, reduces production cost and environment pollution, and the miconazole intermediate with the high chiral ee value (ee is greater than 99) is prepared by using a biological enzyme catalysis method.

The invention relates to lotion combining Chinese and Western medicines and used for killing, preventing and controlling fungal and bacterial diseases on dog / cat body surfaces. The lotion consists of bactericidal and bacteriostatic Chinese medicinal herbs such as pseudolarix, smilax glabra, common cnidium fruit, sophora flavescens, cortex dictamni, phellodendron, Szechuan pepper and dried alum, broad-spectrum efficient miconazole fungicide and efficient chlorhexidine acetate bactericide according to a scientific formula. By combining the Chinese and Western medicines, the bactericidal and bacteriostatic effect is enhanced, the antibacterial spectrum is enlarged, the medicament tolerance produced by long-term use is avoided, and the toxicity of blindly used chemicals is reduced. The lotion for pets has wide spectrum for killing fungi and bacteria, high safety and low toxic or side effects, and can be used for a long term. The formulation can be prepared into spray, lotion, liniment and externally applied ointment by adopting pharmaceutically medicament preparation technologies.

The invention relates to the technical field of medicines, in particular to new application of theaflavin as a synergist of antifungal drugs. Through in vitro experiments, when used together with fluconazole, itraconazole, miconazole, ketoconazole and other antifungal drugs, theaflavin can increase therapeutic effect on slight surface and deep fungus infection to some extent and can restore the effect of the antifungal drugs on drug-resisting fungi. Therefore, the theaflavin can be used as the synergist of the antifungal drugs. The invention provides new application for the theaflavin; when used as the synergist of the antifungal drugs, the theaflavin not only can increase the antifungal effect of the drugs, but also can restore the effect of the antifungal drugs on the drug-resisting fungi in the condition that clinic fungal drug resistance is more and more common and drug resistance degree is more and more serious. The application dosage of the antifungal drugs can be reduced, so that medical expenses can be saved for patients, and the toxic and side effects of the drugs are reduced.

The invention relates to the field of medicine technology and is especially new use of shikonin as an antifungal medicine synergist. The antifungal medicine comprises azole or polyene antifungal medicine and the like, the charge of shikonin is 1-16 mu g / ml in the antifungal medicine. Experiments show that when shikonin is used with the antifungal medicines such as fluconazole, ketoconazole, miconazole or amphotericin B and the like, the treatment effect of superfacial or deep fungal infection can be ensured under the circumstances of reduction of dosage, and the effects of the antifungal medicines to resistant fungi are recovered, thereby that shikonin can be used as antifungal medicine synergist with the advantages of reducing dosages of azole or polyene antifungal medicine so as to reduce side effects of medicines, especially recovering the effects of the antifungal medicines to resistant fungi to treat resistant fungal infection, and having important clinical application value.

There is described antifungal combination use of known antifungal agents such as the azoles or polyenes in combination with a lipopeptide compound antifungal agent. More particularly, the invention relates to antifungal combination use of azols such as fluconazole voriconazole, itraconazole, ketoconazole, miconazole, ER 30346 and SCH 56592; polyenes such as amphotericin B, nystatin, liposomal and lipid forms thereof such as Abelcet, AmBisome and Amphocil; purine or pyrimidine nucleotide inhibitors such as flucytosine; or polyoxins such as nikkomycins, in particular nikkomycin Z or nikkomycin X; other chitin inhibitors; elongation factor inhibitors such as sordarin and analogs thereof; mannan inhibitors such as predamycin, bactericidal / permeability-inducing (BPI) protein products such as XMP.97 or XMP.127; or complex carbohydrate antifungal agents such as CAN-296; with a lipopeptide compound (I) as described herein.

The invention belongs to the field of medicine preparation and relates to a new preparation for treating oral cavity fungal infection. The preparation is realized in the form of a spray preparation of oral gel and specifically contains effective dose of medicines with certain grain size, including miconazole, nystatin, amphotericin and mixture thereof; temperature-sensitive materials, including poloxamer 407, poloxamer 188 and mixture thereof; temperature-sensitive adjuvant polyols, including propylene glycol and glycerol; solvent, including water, ethanol or mixture thereof. The combination can greatly reduce the viscosity of oral-sensitive gel, so that the gel can be quantitatively and smoothly sprayed to oral affected parts to achieve a very good curative effect.

The suppository for controlling sexual spread of AIDS contains Zidovudine and substrate and each grain of the suppository may also contains Aciclovir 0-500 mg, Amphotercin 0-50 mg, Miconazole 0-300 mg, surfactant 0-100 mg and deodorant 0-100 mg. It is applied locally to urogenital system and this results in less toxic side effect and high biological utilization. Its Aciclovir is converted in vivo into triphophate compound to interfere the duplication of herpes simple xvirus DNA and to inhibit herpes virus, cytomegalo virus and EB virus; Amphotercin is used for treating vaginalmucous membrane infection; and Miconazole has broad-spectrum antifungal function.

The invention relates to the technical field of medicaments, in particular to novel application of sodium houttuyfonate as a synergist of an antifungal medicament. The antifungal medicament is an azole or polyene antifungal medicament; and 1 to 16mu g of sodium houttuyfonate is added into each 1ml of antifungal medicament. Experiments prove that: when the sodium houttuyfonate is combined with the antifungal medicament such as fluconazole, ketoconazole, miconazole or amphotercin B, and the like, the treatment effect of the sodium houttuyfonate on superficial or deep fungal infection can be ensured under the condition of reducing the dosage and the sodium houttuyfonate can make the antifungal medicament recover the effect on medicament-resistant fungi, so the sodium houttuyfonate can be used as the synergist of the antifungal medicament. The sodium houttuyfonate serving as the synergist of the antifungal medicament can reduce the dosage of the azole or polyene antifungal medicament so as to reduce the toxic and side effects of the medicament; and particularly, the sodium houttuyfonate makes the antifungal medicament recover the effect on the medicament-resistant fungi, effectively treats fungal infection, particularly medicament-resistant fungal infection, and has important clinical application value.

The invention belongs to the technical field of medicine, and more specifically relates to applications of traditional Chinese medicine sanguisorba officinalis in preparing an antifungal drug synergist. It is confirmed by in vivo experiments that sanguisorba officinalis possesses synergistic effects with routine antifungal drugs such as fluconazole, miconazole, caspofungin, and amphotericin B; with regard to drug resistance funguses, when the antifungal drugs are combined with sanguisorba officinalis, drug dose of the routine antifungal drugs can be reduced obviously, inhibiting effects of the routine antifungal drugs on funguses can be improved to different degrees, effects of the antifungal drugs on the drug resistance funguses can be recovered, and inhibiting effects on the drug resistance funguses are improved. Novel applications of traditional Chinese medicine sanguisorba officinalis are provided; clinical fungus drug resistance can be widely observed, and drug resistant degree becomes higher, drug dose of the antifungal drugs can be reduced, medical cost is reduced for patients, and drug toxic and side effects are reduced.

There is described antifungal combination therapy comprising the use of known antifungal agents such as the azoles or polyenes in combination with a pneumocandin derivative antifungal agent. More particularly, the invention relates to antifungal combination therapy comprising the use of azoles such as fluconazole, voriconazole, itraconazole, ketoconazole, miconazole, ER 30346, SCH 56592; polyenes such as amphotericin B, nystatin or liposomal and lipid forms thereof such as Abelcet, AmBisome and Amphocil; purine or pyrimidine nucleotide inhibitors such as flucytosine; or polyoxins such as nikkomycins, in particular nikkomycin Z or other chitin inhibitors, elongation factor inhibitors such as sordarin and analogs thereof, mannan inhibitors such as predamycin, bactericidal / permeability-inducing (BPI) protein products such as XMP.97 or XMP.127 or complex carbohydrate antifungal agents such as CAN-296 in combination with a pneumocandin derivative as described herein.

Fungicide formed by compounding prothioconazole and miconazole and used for preventing and treating rice blast is characterized by being prepared by compounding the prothioconazole and the miconazole which serve as base material according to the mass ratio of the miconazole to the prothioconazole being from 1:1 to 1:7; and the prothioconazole is an original medicine with the mass percentage being 98 percent, and the miconazole is an original medicine with the mass percentage being 98 percent. Preferably, the fungicide for preventing and treating rice blast is compound fungicide prepared by compounding the prothioconazole and the miconazole according to the mass ratio of the miconazole to the prothioconazole being 1:3. According to the fungicide, after the two base materials are mixed, the two base materials do not generate chemical reaction, so the fungicide has remarkable synergistic effect, is safe to use, has high toxic activity which is obviously higher than that of miconazole and prothioconazole single agents, and is suitable for the vast rural areas to prevent and treat rice blast.

The invention discloses acinetobacter sp. ZJPH1806 and an application thereof to preparation of a miconazole chiral intermediate. 2,2',4'-trichloroacetophenone is subjected to asymmetric reduction toprepare (R)-2-chlorine-1-(2,4-chlorophenyl) ethanol, and obtained products are high in optical purity. In a phosphate buffer liquid system of which the pH is 7.6, glycerine is used as an auxiliary substrate, 2g / L of a substrate is added, a reaction is performed for 26h, the yield of R-type products is 83.2%, and e.e. value is greater than 99.9%.

Disclosed herein are topical compositions and treatment methods for protecting the skin and alleviating symptoms of dermatitis, including “diaper rash”, and skin irritation caused by nonspecific dermatitis conditions and those associated with increased bacterial and / or yeast growth. The compositions may include petroleum jelly, lanolin, aluminum hydroxide, mineral oil, miconazole and bacitracin. The compositions may be delivered topically and formulated in ointments, creams, and lotions.

The invention relates to the technical field of medicines and discloses a new use of forsythiaside as a synergist of antifungal agents. In vivo and in vitro experiments show that the forsythiaside can be combined with the antifungal agents, such as fluconazole, itraconazole, miconazole, ketoconazole and the like, thereby improving the treatment effect of superficial and deep fungal infection with different degrees, leading the antifungal agents to recover the role to fungi with drug resistance and further using the forsythiaside as the synergist of the antifungal agents. The invention opens up the new use of the forsythiaside, and the use of the forsythiaside as the synergist of the antifungal agents can not only improve the antifungal role of drugs, but also lead the antifungal agents to recover the role to the fungi with drug resistance under the situations that the clinical drug resistance of the fungi is increasingly common and the drug resistance degree is increasingly serious, and further reduce the dosage of the antifungal agents, thereby saving medical expenses for patients and reducing toxicity and side effects of the drugs.

The invention relates to an external-application medicament for treating beriberi and pruritus, and aims to solve the technical problems that the curative effect on the beriberi is not good, the period is long and the beriberi can easily have a relapse in the prior art. The external-application medicament mainly comprises the following bulk drugs in parts by weight: 5-10 parts of red sage root, 1-2 parts of borneol, 10-20 parts of fructus cnidii, 10-15 parts of salicylic acid and 40-53 parts of miconazole. The bulk drugs are weighed according to the weight parts and are mixed together to prepare an ointment. The external-application medicament has a good curative effect on treating beriberi, tinea pedis and pruritus, and has the characteristics that sweat glands are not sealed, fungi are killed, the effects of relieving itching and diminishing inflammation are achieved, the side effect is small, the curative effect is quick, and recurrence is not easily caused.

The invention discloses western medicine composition for preventing and treating acne. The western medicine composition is prepared from raw materials in parts by weight as follows: 5-8 parts of oxytetracycline tablets, 3-5 parts of analgin tablets, 5-8 parts of normal saline, 3-5 parts of compound dexamethasone acetate ointment, 3-10 parts of fluocinonide ointment, 4-6 parts of loratadine tablets, 0.5-2 parts of retinoic acid, 1-3 parts of Xuesaitong tablets, 5-10 parts of bird's nests, 1-3 parts of aloe vera gel, 2-5 parts of miconazole cream, 5-10 parts of sunflower seed oil and 1-3 parts of Amprenavir. The western medicine composition has a synergistic effect through compounding of the raw materials and can effectively inhibit acne growth, promote acne inflammation diminishing and recovery, effectively remove acne marks and promote skin regeneration; furthermore, the western medicine composition adopts the available raw materials, is low in cost, good in curative effect and convenient to apply and has few toxic and side effects; besides, the skin can become fine, smooth and elastic when the western medicine composition is applied to the normal skin.

The present invention relates to medicine composition for treating vulval and / or vaginal diseases. The medicine composition for treating vulval and / or vaginal diseases contains promestriene and miconazole in the weight ratio of 1 to 5-1 to 8 as the active components. The daily dose of the medicine composition includes promestriene 6-10 mg, preferably 7 mg; and miconazole 30-80 mg, preferably 50 mg. The medicine composition is prepared into vagina administrating preparation forms, such as suppository, capsule, tablet, etc.

The invention discloses a western medicine composition for treating scalds. The western medicine composition comprises the following raw materials in parts by weight: 10-20 parts of fluocinonide, 10-20 parts of loratadine tablets, 1-5 parts of tretinoin, 5-8 parts of sanqi panax notoginseng, 5-8 parts of erythrocin, 1-3 parts of somedon, 10-15 parts of honey, 1-3 parts of aloe vera gel, 2-5 parts of miconazole, and 5-10 parts of rapeseed oil. The western medicine composition plays synergistic effects by compounding the raw materials, can effectively treat various scalds, can immediately achieve the purposes of relieving itching, relieving pain and eliminating swelling on the scalded skin, and has good curative effects on repairing scald scars, patients are free from relapse after being cured, and thus the western medicine composition is safe and effective; the preparation method of the western medicine composition is simple, the raw materials are easy to obtain, and the production cost is relatively low; and furthermore, the western medicine composition has the advantages of being simple in use method and free from toxic or side effect.

The invention discloses an externally used medicine for curing acne containing honey and royal jelly, comprising tinidazole, miconazole, green ointment, honey, royal jelly and sterile water. The preparation method comprises the following operational steps: grinding metronidazole into powder, sieving; embedding metronidazole powder by miconazole and green ointment, stirring evenly; adding sterile water and stirring evenly; adding honey and royal jelly and stirring evenly. The formulation of the invention is reasonable, has effective effect on curing acne and realizes the aim of resolving the current problems and eliminating the root causes. The added two natural substances honey and royal jelly have the functions of antibiosis and anti inflammatory and can prevent cross infection and adverse effect of the medicine, prevent effectively melanin from precipitating, restore skin resiliency, and adjust skin pH value and oil water balance so that the skin can be white, soft and glossy. The combination of traditional Chinese medicine and western medicine can coordinate with each other and is difficult to generate drug resistance. The medicine is simple in processing and convenient in use, and provides an ideal medicine for cooperating with acne and operation treatment.